Wednesday, 26 August 2026European Markets

EBUSCO HOLDING Stock Over 27% Down In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of EBUSCO HOLDING (AEX-Index: EBUS.AS) fell by a staggering 27.12% in 21 sessions from €12.61 to €9.19 at 05:11 EST on Tuesday, after two consecutive sessions in a row of gains. AEX-Index is jumping 0.54% to €759.84, following the last session's upward trend.

EBUSCO HOLDING's last close was €9.19, 63.68% below its 52-week high of €25.30.

About EBUSCO HOLDING

Ebusco Holding N.V., together with its subsidiaries, develops, manufactures, and distributes zero emission buses, batteries, and charging systems in the Netherlands, Belgium, France, Germany, Norway, Switzerland, and Denmark. It also sells ancillary products and services; and provides electric vehicle ecosystem repair and maintenance services. Ebusco Holding N.V. was founded in 2010 and is headquartered in Deurne, the Netherlands.

Earnings Per Share

As for profitability, EBUSCO HOLDING has a trailing twelve months EPS of €322.07.

PE Ratio

EBUSCO HOLDING has a trailing twelve months price to earnings ratio of 0.03. Meaning, the purchaser of the share is investing €0.03 for every euro of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -11.15%.

More news about EBUSCO HOLDING (EBUS.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com